rs6053005 — SLC23A2

Intronic variant in the SVCT2 tissue vitamin C transporter — associated with differences in plasma vitamin C levels in the EPIC cohort

See your personal result for SLC23A2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC23A2 rs6053005 — Tissue Vitamin C Delivery and the SVCT2 Transporter

Vitamin C reaches your body's tissues in two steps: absorption from the gut (handled by SVCT111 SVCT1
Sodium-dependent Vitamin C Transporter 1, encoded by SLC23A1 — responsible for intestinal absorption and renal reabsorption of vitamin C), followed by selective uptake into individual cells and organs (handled by SVCT222 SVCT2
Sodium-dependent Vitamin C Transporter 2, encoded by SLC23A2 — responsible for cellular uptake of vitamin C in metabolically demanding tissues such as brain, adrenal gland, and eyes). While SVCT1 controls whole-body vitamin C homeostasis, SVCT2 ensures that the organs with the highest metabolic demand — brain, adrenal cortex, and retina — receive preferential access to circulating ascorbate. A common intronic variant at rs6053005 in SLC23A2 has been identified as an independent predictor of plasma vitamin C levels, suggesting that changes in SVCT2 expression or splicing efficiency measurably influence how well the body distributes this essential antioxidant.

The Mechanism

rs6053005 sits within an intron of SLC23A2 on chromosome 20 (GRCh38 position 4,977,054). Intronic variants are not silent — they can affect pre-mRNA splicing33 pre-mRNA splicing
The process by which introns are removed and exons joined to produce a mature mRNA. Intronic variants near splice sites or within regulatory elements can alter the efficiency or fidelity of this process, changing the amount or form of protein produced, enhancer/silencer activity within the intron, or the stability of the final mRNA transcript. The precise molecular consequence of rs6053005 has not been characterized in functional assays, but its association with circulating vitamin C concentrations implies a real, if indirect, effect on SVCT2 expression or activity.

SVCT2 is expressed most highly in the adrenal gland (RPKM 40.7) and brain (RPKM 20.8). These tissues accumulate intracellular vitamin C at concentrations 10- to 100-fold higher than plasma — the adrenal gland reaches millimolar concentrations, using ascorbate as a cofactor for catecholamine synthesis (dopamine-to-norepinephrine conversion). The brain uses it for neurotransmitter synthesis, antioxidant defense, and collagen formation in the extracellular matrix. Any impairment in SVCT2 activity would preferentially affect these high-demand tissues.

The Evidence

The primary human evidence comes from the EPIC cohort gastric cancer study44 EPIC cohort gastric cancer study
Duell EJ et al. Vitamin C transporter gene (SLC23A1 and SLC23A2) polymorphisms, plasma vitamin C levels, and gastric cancer risk in the EPIC cohort. Genes Nutr, 2013, which studied 365 gastric cancer cases and 1,284 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. In multivariable linear regression models, four SNPs independently predicted plasma vitamin C levels: rs11950646 (SLC23A1), rs33972313 (SLC23A1), rs6053005 (SLC23A2), and rs6133175 (SLC23A2). The study did not find a direct association between rs6053005 and gastric cancer risk independently, but SLC23A2 haplotypes — blocks of variants inherited together — were associated with overall gastric cancer, non-cardia gastric cancer, and intestinal-type gastric cancer, suggesting that the gene's role in mucosal tissue vitamin C delivery is clinically meaningful.

The evidence base for rs6053005 as an individual SNP is more limited than for the well-validated SLC23A1 variant rs33972313. The EPIC study is the only publication to directly implicate rs6053005 in plasma vitamin C variation, and specific effect sizes (beta coefficients, confidence intervals) for this SNP are not publicly available in the abstract record. This places rs6053005 at a moderate evidence level — replicated findings from an appropriately powered cohort study, but without independent replication or functional characterization.

Animal and molecular data support the gene's importance: SVCT2 is the primary vitamin C transporter in metabolically active tissues including brain and adrenal gland. Studies of SLC23A2 regulation55 SLC23A2 regulation
Erichsen HC et al. Differential regulation of the human sodium-dependent vitamin C transporters SLC23A1 and SLC23A2 by conditions of oxidative stress. Am J Clin Nutr, 2004 show that SLC23A2 expression responds to oxidative stress conditions, highlighting the transporter's role in maintaining tissue ascorbate under physiological challenge. This means plasma vitamin C measurements may not fully reflect tissue-level adequacy in carriers of reduced-function variants.

Practical Implications

The actionable picture for rs6053005 is similar to rs33972313 but with a distinct biological rationale. Where SVCT1 variants reduce how much vitamin C gets absorbed and retained systemically, SVCT2 variants affect how well circulating vitamin C is delivered into cells and high-demand tissues. The practical implication is the same: carriers of the T allele may benefit from ensuring consistent, adequate vitamin C intake to maintain sufficient plasma levels for SVCT2 to work with.

Plasma vitamin C ranges: adequate is above 28 umol/L, suboptimal is 11-28 umol/L, and below 11 umol/L indicates deficiency. The T allele at rs6053005 appears to be associated with modestly lower circulating levels. Since SVCT2 is particularly important for brain and adrenal function, any reduction in plasma vitamin C availability amplifies the risk of suboptimal delivery to these priority tissues.

Interactions

rs6053005 acts as a second, independent signal in the vitamin C transport system alongside rs3397231366 rs33972313
SLC23A1 Val264Met — affects intestinal absorption and renal reabsorption of vitamin C, the primary whole-body regulator (SLC23A1 Val264Met). In the EPIC cohort, both SLC23A1 and SLC23A2 variants independently predicted plasma vitamin C, suggesting the two transporters contribute additively to circulating ascorbate levels. Individuals carrying risk alleles at both loci may have compounded reductions in both systemic availability and tissue delivery.

rs6133175, another SLC23A2 intronic variant approximately 66 kb upstream of rs6053005, was also independently associated with plasma vitamin C in the same EPIC analysis, suggesting the SLC23A2 locus contains multiple regulatory variants affecting SVCT2 expression.

Nutrient Interactions

vitamin C altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal SVCT2 Function Normal

Common variant — normal tissue vitamin C distribution

SLC23A2 encodes SVCT2, the transporter responsible for moving circulating vitamin C into metabolically demanding cells. The CC genotype at rs6053005 represents the reference configuration, with no evidence of altered SVCT2 expression or splicing. In the EPIC cohort analysis, CC homozygotes were not flagged as having lower plasma vitamin C compared to the overall population.

Your daily vitamin C requirement (75 mg for women, 90 mg for men per US RDA; smokers add 35 mg) is sufficient to maintain adequate plasma levels that SVCT2 can then efficiently deliver to tissues.

CT One T Allele Intermediate

One copy of the T allele — modestly lower plasma vitamin C predicted

As a heterozygous carrier, you have one normal C allele and one T allele at this intronic position. The biological mechanism likely involves altered SVCT2 expression or mRNA splicing efficiency. SVCT2 is the primary vitamin C transporter in metabolically active tissues (brain, adrenal gland), and its expression responds to oxidative stress — meaning tissues most dependent on SVCT2 may be more sensitive to reduced transporter efficiency than plasma levels suggest.

This variant acts as a second, independent signal alongside the SLC23A1 rs33972313 variant. If you also carry the T allele at rs33972313, both absorption and tissue delivery of vitamin C are mildly impaired, compounding the effect.

TT Two T Alleles Reduced

Two copies of the T allele — reduced plasma vitamin C levels predicted

With two T alleles, both copies of your SLC23A2 gene carry the intronic variant. This is the configuration expected to have the largest effect on SVCT2 expression or splicing at this locus. The brain, which accumulates vitamin C at concentrations up to 10 mM intracellularly (vs. ~50-80 umol/L plasma), is particularly dependent on functional SVCT2 for this gradient. The adrenal cortex uses millimolar ascorbate as a cofactor for catecholamine biosynthesis (converting dopamine to norepinephrine via dopamine beta-hydroxylase).

The evidence for rs6053005 specifically is from a single cohort study, so the per-allele effect size is not precisely quantified. The effect direction is consistent with the broader biology of SVCT2 — reduced transporter function leads to lower tissue vitamin C concentrations. Combined with any SLC23A1 variant affecting gut absorption, TT homozygotes face both a supply reduction and a delivery reduction.